Articles On Alchemia (ASX:ACL)

Australian Clinical Labs (ASX: ACL) is set to nearly double its number of collection centres in NSW while solidifying its presence in QLD through the $70 million acquisition of Medlab Pathology. After recently lifting its December half rev...

The healthcare sector is home to a number of companies with the potential to grow strongly in the future. Two that investors might want to get better acquainted with are listed below. Here’s why they are highly rated: Australian Clinical L...

Whether the market is up or down, there is one type of ASX stock that investors love — businesses that upgrade their expected results. If a company finds that it’s doing better than previously thought, or it’s consistently hitting the high...

The healthcare sector is having a tough week and has fallen heavily. For example, the S&P/ASX 200 Health Care index is down 7.5% since this time last week. While this is disappointing, it may have created a buying opportunity for inves...

The ASX 200 health stocks index (XHJ) is falling sharply by 2.40% at the time of writing, compared to the broader ASX 200 index which fell by 0.60%. Imaging tech company, Mach7 Tech (ASX:M7T), jumped 6.5% higher this morning after receiving...

The COVID-19 outbreaks in NSW and Victoria have led to a surge in demand for testing, and that trend looks set to show up in the bottom line of pathology network Australian Clinical Labs (ASX:ACL). Australian Clinical Labs, which listed in...

Wall Street mixed as US Fed sends warning on inflation US stock markets finished in mixed territories on Monday, with tech stocks being the main laggards. The Dow Jones rose by 0.21%, but the S&P 500 fell by 0.28% and the tech heavy Nas...

The WAM Capital Limited (ASX: WAM) share price has risen by 6% over the last month. What may be next for the listed investment company (LIC)? What is WAM Capital? For readers that haven’t heard of WAM Capital before, it’s a LIC. The purpos...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

The Australian Clinical Labs Ltd (ASX: ACL) share price has leapt into the green on Thursday as the pathology services company reported its FY21 earnings. Australian Clinical Labs shares are now changing hands at $4.55 apiece, up 8.3% aft...

Top performers from today’s list companies releasing annual results included Swoop (ASX:SWP), Australian Clinical Labs (ASX:ACL) and Fineos (ASX:FCL).   Australian Clinical Labs (ASX:ACL) This company is a pathology stock and like industry...

The ASX 200 health stocks index (XHJ) fell by 1.55% this morning, compared to the broader index which dropped by 0.67%. Topical and and dermatological specialist, Acrux (ASX:ACR), announced that its generic Testosterone Topical Solution USP...

The fund manager Wilson Asset Management (WAM) has told investors about two ASX shares that it has in its portfolio. WAM operates several listed investment companies (LICs). Some focus on larger companies like WAM Leaders Ltd (ASX: WLE). T...

Leading fund manager Wilson Asset Management (WAM) has revealed two ASX shares that it rates as buys within the WAM Research Limited (ASX: WAX) portfolio. WAM operates several listed investment companies (LICs). Two of those LICs are WAM C...

The cavalcade of life science initial public offers (IPOs) and ASX listings shows few signs of receding, with BCAL Diagnostics (ASX:BDX) last week braving the bourse amid choppy global market conditions. In the life sciences IPO Olympiad, w...

An ASX share that only listed a few weeks ago is being ignored by investors, even though next month’s reporting season could light a fire under it. That’s according to Wilson Asset Management portfolio managers Matthew Haupt, Catriona Burn...

The COVID-19 lockdowns of our two biggest cities have prompted brokers to upgrade their earnings calls on several ASX 200 shares. While the protracted lockdowns in Sydney and Melbourne are weighing on the S&P/ASX 200 Index (Index:^AXJO...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

Point of care diagnostic test provider Lumos Diagnostics (ASX:LDX) is set to list on the ASX on July 5. The company was founded in Melbourne in 2015 and is still headquartered there but has manufacturing facilities in California and Florida...

The first major test for a newly listed ASX stocks is if it can meet or exceed its prospectus forecasts, and Lynch Group (ASX:LGL) passed that test today. Lynch Group has only been listed on the ASX for two months, although its history goes...

The Australian Clinical Labs Ltd (ASX: ACL) share price is pushing higher on Monday. In afternoon trade, the pathology services provider’s shares are up 2% to $3.76. Despite this gain, the Australian Clinical Labs share price is still trad...

The Australian Clinical Labs Ltd (ASX: ACL) share price climbed to a new high of $3.88 during trading today. This follows the pathology service provider’s announcement that it has upgraded its earnings forecast for the 2021 financial year....

Summary The S&P/ASX 200 scaled a new high on Thursday, ending 0.6% up at 7260.1. The index gained as much as 0.9% to hit a fresh intraday high of 7281.8. Australian engineering company Worley was the top gainer, rising 8.13% to AU...

A big surge in energy shares led the ASX into positive territory for the second day in a row. The ASX 200 closed 0.59 per cent higher at 7,260 points although the ASX Emerging Companies Index closed 0.28 per cent lower at 2,188. Energy led...

ShareCafeAPH Helping Humans, and Pets, Through Hemp   One of the more intriguing aspects of the stock market in recent years has been the rehabilitation of cannabis, in the form of the burgeoning medicinal cannabis sector; and Australian P...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

There are many reasons why a company might change its name, from being taken over to hiding a shady past. This year 114 companies have changed their name. Family cyber security provider Wangle Technologies became the much more fitting Famil...

Once biotechnology company Alchemia has acquired hemp grower Australian Primary Hemp (ASX: APH) as part of a shift into hemp production and distribution. To complete its reverse takeover (RTO) listing, the company raised $5.7 million by iss...

Imugene Limited (ASX: IMU), an Australian-headquartered clinical-stage immuno-oncology company, focusses on the development of emerging immunotherapies to enhance the efficacy of cancer treatments. The company utilises its unique platform t...

The ASX’s 32 tradeable pot stocks and pot stock wannabees are down 17 per cent over the last 12 months. The Small Ords (ASX:XSO) has risen 1.62 per cent in the same time, and the All Ords (ASX:XAO) and the ASX200 (ASX:XJO) are both up over...

Vigilance and self-awareness on the performance of stocks is perhaps the most effective catalyst that drives one on the path to become a successful investor/trader. Potential shortfalls, sudden surges, certain market anomalies, adverse econ...

It has been a few lean years at Alchemia (ASX: ACL). In October 2014 the Phase III trial of an anti-cancer drug failed and its shares plummeted. As often happens with failed biotechs, the next several months (and years) were spent looking f...